ArticleAnnals of neurology2021
Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease.
Article in Annals of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Optical coherence tomography angiography in Parkinson's disease: a systematic review and meta-analysis.Eye (London, England) · 2023Pooled it
- The Cognitive Profile of Atypical Parkinsonism: A Meta-Analysis.Neuropsychology review · 2023Pooled it
- Retina thickness in atypical parkinsonism: a systematic review and meta-analysis.Journal of neurology · 2022Pooled it
- Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2022Pooled it
- Dorsal and ventral stream visuoperceptual processing deficits in Lewy body disease.Journal of neurology · 2026Article
- MRI-Based Texture Analysis of the Extraocular Optic Nerve in Idiopathic Parkinson's Disease.Journal of clinical medicine · 2026Article
- Early Detection of Dementia Through Spectralis Optical Coherence Tomography in a Taiwanese Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Distinct cellular localization of α- synuclein and β-synuclein in the chick retina.Brain structure & function · 2025Article
- Optical coherence tomography - A possible biomarker in early huntington's disease.Neurological research and practice · 2025Article
- Optical coherence tomography reveals retinal structural abnormalities in α-synucleinopathies: insights from the Padua-CESNE cohort.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Recent Optical Coherence Tomography (OCT) Innovations for Increased Accessibility and Remote Surveillance.Bioengineering (Basel, Switzerland) · 2025Review
- Amygdala Neurodegeneration: A Key Driver of Visual Dysfunction in Parkinson's Disease.Annals of clinical and translational neurology · 2025Article
- The Combination of Retinal Neurovascular Unit Changes With Carotid Artery Stenosis Enhances the Prediction of Ischemic Stroke.Translational vision science & technology · 2025Article
- Dynamics of retinal changes in early-stage Parkinson's disease.Acta neuropathologica communications · 2025Article
- Neuroretinal and microvascular retinal features in dementia with Lewy body assessed by optical coherence tomography angiography.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Retinal biomarkers in schizophrenia spectrum disorders: evidence and implications for the neurodevelopmental and neurodegenerative models.Frontiers in medicine · 2025Review
- Idiopathic Parkinson's Disease and Neuro-ophthalmological Findings: A Study on Neurodegeneration in the Retinal Nerve Fiber Layer and Cognitive Functions.Noro psikiyatri arsivi · 2025Article
- Macular structural integrity estimates are associated with Parkinson's disease genetic risk.Acta neuropathologica communications · 2024Article
- Visual dysfunction in dementia with Lewy bodies.Current neurology and neuroscience reports · 2024Review
- Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions.Nature communications · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD).
methodsPatients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K-SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell-inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs.
resultsGCIPL thickness in the parafoveal region (1- to 3-mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10-11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03-10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration.
interpretationOur results provide evidence of the potential use of optical coherence tomography-measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165-176.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.